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Available online 3 June 2013Trametenolic acid B (TAB), the bioactive component in the Trametes lactinea (Berk.) Pat, was
reported to possess cytotoxic activities and thrombin inhibiting effects. This studywas performed
to investigate the effects of TAB on H+/K+-ATPase and gastric cancer. The H+/K+-ATPase
inhibitory activity was determined by gastric parietal cells. Compared to the normal control
group, TAB (10, 20, 40 and 80 μg/mL) inhibited the H+/K+-ATPase activity by 15.97, 16.96, 24.86
and 16.25%, respectively. In the study, 36 Kunming mice were randomly divided into six groups:
control, model, TAB-L (TAB, 5 mg/kg/day, i.g.), TAB-M (TAB, 20 mg/kg/day, i.g.), TAB-H (TAB,
40 mg/kg/day, i.g.) and omeprazole (OL, 10 mg/kg/day, i.g.). All mice except the control group
were administrated with anhydrous alcohol (5.0 mL/kg, i.g.) for induced gastric-ulcer 1 h after
the 5th day. At the same time, the control mice were given the same volume of physiological
saline. After 4 h, TAB was evaluated for H+/K+-ATPase inhibitory activities of ulcerative gaster,
gastric ulcer index and ulcer inhibition. In vitro, the anti-proliferation effect of TAB to gastric
cancer cell (HGC-27) in acid environmentwas detected byMTT, and the apoptosismorphological
changes were also observed by Hoechst 33258 dye assay. The results indicated that TAB inhibited
moderatelyH+/K+-ATPase activity in vitro. Compared to themodel group, TAB showed anti-ulcer
effects in gastric tissue with the dosages of 20 and 5 mg/kg in vivo. Apart from that, TAB could
selectively inhibit gastric cancer cell viability and reduce cell apoptosis against HGC-27 cells at low
doses in acid environment.




Anti-gastric cancer1. IntroductionAcid-related disorders are highly prevalent in the developed






r B.V. Open access under CC BYand cause heavy burden on health care systems [1]. Gastric acid
was identified as an important pathogenic factor for most
prevalent gastrointestinal disorders such as duodenal ulcer and
gastroesophageal reflux disease [2,3]. The gastric H+/K+-ATPase
is the proton pump responsible for the final step of acid secretion
in the stomach, which locates in gastric membrane vesicles and
catalyzes the electro-neutral exchange of intracellular H+ and
extracellular K+ coupled with the hydrolysis of cytoplasmic ATP
[4,5]. Drugs for treatment of acid-related diseases are ultimately
implemented through inhibiting H+/K+-ATPase activity [3,6,7].
A variety of heterocyclic structures has been described in license.
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example omeprazole, esomeprazole, lansoprazole and
pantoprazole, bind to the H+/K+-ATPase and have been
available as therapeutics for a long time [8,9]. However, the
adverse effect of long-term use of these drugs caused strong
desire for investigators to developnewalternativemedicine [10].
Peptic ulcer mainly occurs in the stomach and duodenal
ampulla, which is a common digestive disease with increasing
incidence year by year [11]. Gastric ulcer and duodenal ulcer are
the common ulcers, and young males are easy to infect these
diseases. It is apt to cause gastric cancer and other complica-
tions if not treated promptly [12]. There is a certain correlation
between gastric ulcer and gastric cancer [13,14], and gastric
ulcer is generally not cancerous in the early 3–5 years of its
occurrence, but the risk of gastric cancer and the correlation
were significantly increased with the duration and extension of
pathogenesis, which are consistent with the pathogenesis of
gastric. It thoroughly indicates that untimely treatment and
allowing the development of gastric ulcer without restriction
will greatly increase the chance of ultimate cancer [15,16].
Therefore, it is of great importance to enhance early prevention
and treatment of gastric ulcer. Lots of traditional Chinese foods
were reported to have positive effect on the gastric ulcer, and
the active ingredients and anti-gastric ulcer mechanisms were
worthy to be investigated.
Triterpenoids are kinds of economically andmedicinally
important natural products with wide uses for their
attractive pharmacological medicinal activities [17]. The
lanostane-type triterpenoid 3β-hydroxylanosta-8, 24-diene-
21-oic acid (Trametenolic acid B, TAB) was the bioactive
component of the Trametes lactinea (Berk.) Pat, isolated from
China traditional Tujia food, fermented corn,whichwas reported
to possess cytotoxic activities [18] and antimicrobial activity
[19]. To the best of our knowledge, the anti-gastric ulcer and
anti-gastric cancer effect of TAB was seldom investigated. In this
work, the H+/K+-ATPase inhibitory activity, anti-proliferation
effects against gastric cancer cells and computer-aided mecha-
nism studies for TAB were firstly reported.2. Materials and methods
2.1. Materials
Dulbecco's modified Eagle's medium (DMEM) and L-gluta-
mine were obtained from Gibco BRL (Grand Island, NY, U.S.A.).
Fetal bovine serum (FBS)was purchased from ICNBiological, Inc.
(Aurora, OH, U.S.A.) 0.25% Trypsin was purchased from Sino-
American Biotechnology Company (Darmstadt, Germany). 3-(4,
5-Dimethyl-2-thiazolyl)-2,3-di-phenyl-2H-tetrazolium bromide
(MTT), streptomycin and penicillin were purchased fromWako
Pure Chemical Ind, Ltd (Osaka, Japan). Omeprazolewas obtained
from AstraZeneca. Trypan blue was purchased from Nanjing
KeyGEN Biotech Co. Ltd. The H+/K+-ATPase ELISA kits were
obtained from Nangjing Jiancheng Bioengineering Institute. All
chemical reagents andmaterials were purchased from commer-
cial suppliers and used without further purification. Column
chromatographywas performedusing a 200–300mesh silica gel.
NMR spectra (DMSO-d6) were recorded on Bruker Ultrashield™
400 MHz Plus spectrometer. Elemental analyses were carried
out with a Vario EL III elementary analysis instrument.Male Kunming mice weighing 18–22 g were obtained
from the LaboratoryAnimal Services Centre, China ThreeGorges
University, Yichang, China. The animals were maintained on a
12-h light/dark cycle under regulated temperature (22 ± 2 °C)
and humidity (50 ± 10%), fed with standard diet and water ad
libitum, and when necessary, animals were deprived from food
allowing free access to water 12 h before the experiment.
Experiments were performed in accordance with the Guide for
the Care and Use of Laboratory Animals of China Three Gorges
University, and approved by the ethics committee. The whole
laboratory procedure was carried out under the permission and
surveillance of the ethics committee.
TAB and OL were dissolved in DMSO at high concentra-
tions. Once dissolved in the solvent, all compounds were stored
at−20 °C. Compounds were diluted to relevant concentrations
with medium or physiological saline when in vivo and in vitro
experiments.
2.2. Experimental design
2.2.1. Extraction and isolation of TAB
T. lactineawas succeeded in culture in our laboratory, which
was identified as T. lactinea (Berk.) Pat. by professor Shaobai
Wang of Hubei Sanxia Science and Technology School. The
myceliumof T. lactinea (120 g)was extractedwith ethanol (95%)
under 50 °C for 3 h. After the removal of solvent under reduced
pressure, 63 g extract was obtained, which was extracted with
ethyl acetate and gave 35 g residue [20–22]. Finally, the
3β-hydroxylanosta-8, 24-diene-21-oic acid (Trametenolic acid
B, 7.0 g, Yield: 5.8%) was obtained with the purity of >98% by
silica gel column chromatography (n-hexane/EtOAc = 4:1, v/v),
which was characterized by 1H NMR on Bruker Ultrashield™
400 MHz Plus spectrometer, and the spectra were identical to
literature reports (its structure was shown in Fig. 1). Its data of
13CNMRand 1HNMR spectra are as follows: 13CNMR(DMSO-d6,
500 MHz):177.1, 134.4, 133.5, 131.2, 124.0, 76.9, 50.2, 49.2, 47.6,
46.7, 43.9, 38.7, 36.7, 35.4, 32.3, 30.2, 28.5, 28.2, 27.7, 26.6, 26.1,
25.7, 25.6, 24.2, 20.4, 19.1, 18.0, 17.5, 15. 9, 15.7; 1H NMR
(DMSO-d6, 500 MHz): 0.68 (s, 3H), 0.69 (s, 3H), 0.81 (s, 3H), 0.90
(s, 3H), 0.90 (s, 3H), 1.52 (s, 3H), 1.62 (s, 3H), 4.25 (d, J = 3.5 Hz,
1H), 5.06 (s, 1H), 11.96 (s, 1H).
2.2.2. Gastric parietal cells
Kunming mice (20 ± 2 g) were sacrificed by cervical dis-
location. The abdomenwas cut open, the stomachwas perfused
through the aorta with phosphate buffered saline (PBS, in mM:
NaCl 149.6, K2HPO4 3, NaH2PO4 0.64, pH 7.4 at 37 °C) and
excised [23]. The fundus and antral regionswere discarded, and
the mucosa was freed from the muscular layers, minced and
digested in trypsin solution (0.25%) for 10 min at 37 °C. The
gastric parietal cell suspension was filtered through a nylon
mesh (750 nm), centrifuged at 1200 rpm for 7 min, rinsed four
times with PBS containing 0.5% bovine serum albumin by
sedimentation, and resuspended in PBS [24,25]. The viability of
the isolated gastric parietal cells was greater than 90% as
determined by trypan-blue dye exclusion [26].
2.2.3. Induction of acute gastric lesions in mice
36 Kunming mice were randomly divided into six groups:
control, model, TAB-L (TAB, 5 mg/kg/day, i.g.), TAB-M (TAB,
20 mg/kg/day, i.g.), TAB-H (TAB, 40 mg/kg/day, i.g.) and
Fig. 1. The structure of Trametenolic acid B.
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group were administrated with anhydrous alcohol (5.0 mL/kg,
i.g.) for gastric-ulcer induction 1 h after the 5th day. At the same
time, control mice were given the same volume of physiological
saline. On the 4th day of feeding, mice were in absolute diet for
12 hwith free access towater before the experiment. On the 5th
day, 1 h later after the last administration, all mice were
administrated with anhydrous alcohol (5.0 mL/kg, i.g.) for
gastric-ulcer induction. The animals were sacrificed by cervical
dislocation after 4 h of alcohol induction. The stomachs were
removed and cut along the greater curvature of the stomach,
discarded the fundus and antral regions, and the glandular
mucosa was quickly weighed, frozen down and stored at −
80 °C for further determinations of H+/K+-ATPase activity
[19,27].
2.2.4. Determination of H+/K+-ATPase activity in vitro
Depurated gastric parietal cell suspension was seeded at
40–50 cells/well in a 96-well plate, in DMEM medium
supplemented with 10% FBS, penicillin and streptomycin.
The cells were incubated with various concentrations of TAB
in a final volume of 200 μL medium for 2 h at 37 °C/5% CO2.
After that, H+/K+-ATPase activity was measured by the
determination of H+/K+-ATPase ELISA kit according to its
instruction. To define one enzyme activity unit is 1 μmol
inorganic phosphorus produced from ATP breaking that by
1 mg of ATP enzymes per hour.
2.2.5. Determination of H+/K+-ATPase activity in vivo
The mucosa from experimental mice was made of a 10%
homogenate in accordance with the proportion of gastric
mucosal tissue weight with saline 1:9 and centrifuged at
2500 rpm for 10 min, and diluted with normal saline into a 2%
homogenate [28–30]. H+/K+-ATPase activity wasmeasured by
the determination of H+/K+-ATPase ELISA kit according to its
instruction.
2.2.6. Molecular docking
The sequence of the human gastric H+/K+-ATPase receptor
(1035 amino acids) was taken from the Swiss-ProtDatabase
(ID: P20648). Through blasting sequences from the Protein
Data Bank [31], the crystal structure of sodium–potassium
ATPase (PDB ID: 2ZXE) [32] was used as a template. Thesequence alignment was carried out using the ClustalW
algorithm [33]. The homology model of H+/K+-ATPase was
generated using MODELLER9v3 [34]. The resultant structure of
the H+/K+-ATPase receptor was subject to the Protein Prepa-
ration Wizard module in Schrödinger [35] as follows: adding
hydrogen, assigning partial charges using the OPLS-2001 force
field, and assigning protonation states. Then the minimization
was carried out using the OPLS force field in the MacroModel
module in Schrödinger. The minimized structure was validated
using PROCHECK [35,36]. The final optimized model of the
gastric H+/K+-ATPase receptorwas used to dock the ligand. The
Glide (SP mode) protocol in the Schrödinger software suite [35]
was carried out between TAB and H+/K+-ATPase. The final
ligand–protein complex was visualized using PyMOL0.99 [37].
2.2.7. Cell culture and cell viability analysis
Human gastric cancer HGC-27 cells and human gastric
mucosa epithelial GES-1 cells were obtained from The Cell Bank
of Type Culture Collection of Chinese Academy of Sciences,
Shanghai Institute of Cell Biology, Chinese Academy of Sciences,
which were cultured in DMEM medium supplemented with
10% FBS and 100 units/mL penicillin in a humidified 5% CO2
atmosphere. Cell viability was assessed by dye exclusion assay.
To evaluate the effect of TAB on cell viability, gastric cancer
HGC-27 cells and normal human gastric epithelial GES-1 cells
were exposed to TAB with different concentrations (10, 5 and
1 μg/mL), and at the same time, HGC-27 cells were treatedwith
drugs in different pH medium including pH 7.5, 6.5, and 5.5 for
24 h, and set omeprazole (10 μg/mL) as the positive control.
The cells were harvested and stainedwith Trypan blue. Survival
(%) was calculated by the following formula: No. of viable cells
(dye excluded cells) / No. of total [38].
2.2.8. Assessment of cell morphological changes
The examination of morphological changes was conducted
by Hoechst 33258 staining of nuclei under the instruction of
the apoptosis-Hoechstwas visualized with a fluorescence
microscope.
2.2.9. Statistical analysis
Each experiment was repeated at least three times. Data
were processed with the SPSS 13.0 for Windows software
package. Values were expressed as mean ± standard
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statistical analysis. A value of P b 0.05 was considered
statistically significant.
3. Results
3.1. Decrease H+/K+-ATPase activity in vitro
The in vitro H+/K+-ATPase inhibitory activity of TAB was
determined by the determination of H+/K+-ATPase ELISA kit.
The results were listed in Fig. 2, and the H+/K+-ATPase in-
hibitory activity of omeprazole significantly decreased showing
percentage protection of 63.7% compared to the control
group. Concomitantly, it was observed that the activity of
H+/K+-ATPase was decreased by TAB (5, 10, 20 and 40 μg/mL)
by 4.72, 15.97, 16.96 and 24.86%, respectively. However, its
inhibition ratio decreased nearly 16.25% at the dose of 80 μg/mL.
Graded doses of TAB at a certain range prevented the activity of
H+/K+-ATPasemoderately that presented dose-dependent, and
the prevention of the activity of H+/K+-ATPase at the high dose
(80 μg/mL) that over this range was more minor.
3.2. Inhibit H+/K+-ATPase activity in vivo
As shown in Fig. 3, the H+/K+-ATPase activity in anhydrous
ethanol-induced mice gaster (ulcer control value = 9.461 ±
1.585 μmol Pi/mg prot/h, mean ± SD) was much higher than
that of the control group (normal control value = 5.229 ±
0.460 μmol Pi/mg prot/h). Furthermore, intragastric admin-
istration treatment with the standard drug, omeprazole
(OL, 10 mg/kg, i.g.) and graded doses of TAB (5 and 20 mg/kg,
i.g.) significantly reduced the H+/K+-ATPase activity in anhy-
drous ethanol-induced mice in 49, 37 and 29%, respectively in
comparison with the model group. And the H+/K+-ATPase
activity in the 40 mg/kg dose group (high dose group value =
6.982 ± 0.377 μmol Pi/mgprot/h)was decreased in 17%, but the
difference was not statistically significant compared with the
control group (P > 0.05).
3.3. Molecular docking
The sequence identity between sodium–potassium ATPase
(PDB ID: 2ZXE) and human gastric H+/K+-ATPase (Swiss-ProtFig. 2. Inhibition of H+/K+-ATPase by different concentrations of TAB in vitro.
Data are shown as the mean ± SD (n = 6). *P b 0.05, **P b 0.01 compared
with control group.ID: P20648) was 64%. The PROCHECK G-factor ranked values
above −0.5 as positive candidates for homology models.
Based on the PROCHECK verification, the G-factor value of the
H+/K+-ATPase model generated by MODELLER was −0.22
(exceeding −0.5). Therefore the model could be regarded as
structurally realistic. The final gastric H+/K+-ATPase homology
model is shown in Fig. 4.
Docking simulation between TAB and H+/K+-ATPase was
performed. The Glide GScore was−4.75. The docking results
were shown in Fig. 5. The hydroxyl and carboxyl groups of TAB
formed hydrogen bonds with the amino acid residues Tyr804
(distance: 2.21 and 2.29 Å), Gln926 (2.31 Å), and Ile816
(1.82 Å).3.4. Effect of TAB on cell proliferation in an acidic
microenvironment
To assess the selective effect of TAB on HGC-27 cell, we
studied responses of these cells to treatments by TAB in normal
pH condition (pH = 7.5). Cells were exposed to TAB over the
concentration range of 1–80 μg/mL. The IC50 values of TAB on
HGC-27 and GES-1 cells were 15.91 and 35.99 μg/mL and the
maximumnon-toxic concentrations (inhibition rates ≤ 10%) of
TAB on these cell lines were 4.07 and 8.81 μg/mL, respectively.
We chose 10 μg/mL as the maximum experimental concentra-
tion, which had nearly no effect on normal gastric parietal cells.
We tested the effects of TAB in different concentrations on cell
growth in culture media maintained at various pHs. As shown
in Fig. 6, TAB significantly attenuated viability of HGC-27 cell in
a dose- and pH-dependent manner. At pH 5.5, TAB (1, 5 and
10 μg/mL) induced cell death proportions to 48.2, 61.4 and
81.5%, respectively. However, TAB showed a slight effect on
normal gastric epithelial cells (GES-1) at these doses. Therewas
more than 80% viability at the dose of 10 μg/mL for GES-1 cells
in Fig. 7.Fig. 3. Effect of TAB on decreasing H+/K+-ATPase in comparison to omeprazole
in anhydrous ethanol-induced gastric ulcer model. Data are shown as the
mean ± SD (n = 6). #P b 0.05, ##P b 0.01 compared with control group;
*P b 0.05, **P b 0.01 compared with model group.
Fig. 4. The homology model of gastric H+/K+-ATPase.
Fig. 5. The docking results of TAB with H+/K+-ATPase.
Fig. 6. Reduction of cell viability by treatment of TAB in culture media
maintained at various pHs. HGC-27 cellswere treatedwith 1, 5 and 10 μg/mL of
TAB for 24 h. Data are shown as themean ± SD (n = 3). #P b 0.05, ##P b 0.01
compared with control group; *P b 0.05, **P b 0.01 compared with different
pH groups.
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To determine whether the proliferation-inhibitory effect
of TAB was related to the induction of apoptosis, morphological
assay of cell death was investigated by a phase contrast micro-
scope. Marked morphological changes could be seen after 24 h
with characterization of shrinkage of cells and loss of the
originally confluent monolayer (Fig. 8B, E, F, G and H), indicating
that apoptotic cell death was induced by treatment of omepra-
zole and TAB. To further examine the morphological changes in
responding to TAB treatment, both control and TAB treated cells
were stained with the fluorescent dye Hoechst 33258 and
visualized by a fluorescent microscope. The control cells were
normal and the nuclei were round and homogeneous (Fig. 8A),
while the cells treated with clitocine after 24 h exhibited the
typical characteristics of apoptosis. In the present study, TAB
(Fig. 1) was isolated from T. lactinea (Berk.) Pat and
characterized via NMR and ESIMS, which could inhibit the
H+/K+-ATPase activity both in vitro and in vivo. The possible
anti-ulcer mechanism of TAB was also analyzed through
computer-aided docking simulation. In vitro, TAB inhibited
H+/K+-ATPase activity at the concentration range of
10–40 μg/mL in a dose-dependent manner. On the other
side, TAB also showed moderate anti-ulcer effects compared
with the omeprazole group in vivo.
4. Discussion
Our present study indicated that TAB possessed moderate
H+/K+-ATPase inhibitory activity in vitro. Compared to themodel group, TAB showed anti-ulcer effects in gastric tissue
with the dosages of 20 and 5 mg/kg in vivo. Apart from that,
TAB could selectively inhibit gastric cancer cell viability and
induce cell apoptosis at low doses in HGC-27 cells in acid
environment.
Most prevalent gastrointestinal disorders and acid-related
diseases such as peptic ulcer are produced by gastric acid. The
gastric H+/K+-ATPase is the proton pump responsible for the
final step of acid secretion in the stomach, which is an important
gastric acid regulator in gastric membrane vesicles. The major
approach in the development of drugs against these acid-related
diseases is still by inhibiting the gastric H+/K+-ATPase activity.
Nevertheless, the adverse effect of long-term use of these drugs
is one of the major limitations in clinical applications [7,13].
Furthermore, gastric ulcer and duodenal ulcer are sometimes apt
to cause gastric cancer and other complications if not treated
promptly. Our results indicated that graded doses of TAB
possessed moderate H+/K+-ATPase inhibitory activity in vitro.
Compared with the model group, TAB (5 and 20 mg/kg, i.g.)
could also reduce the H+/K+-ATPase activity in vivo on ethanol-
Fig. 7. Survival rate of GES-1 cells treated by TABwith 1, 5and 10 μg/mL for 24 h.
Data are shownas themean ± SD (n = 3). #P b 0.05, ##P b 0.01 comparedwith
control group.
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At the dose of 40 mg/kg, the inhibitory effect of TABwas inferior
to the doses of 20 mg/kg and 5 mg/kg. These results wereFig. 8. Morphological changes of HGC-27 cells after treatment or untreated with om
groupwas observed by phase-contrast and fluorescencemicroscope. A, B, C, D, E, F, G a
and TAB treated cells group (1, 5, 10, 20, 40 and 80 μg/mL) in order.consistent with the results in vitro, which indicated that the
inhibition on H+/K+-ATPase activity was notable in certain
doses (10–40 μg/mL in vitro, 5 and 20 mg/kg in vivo), but the
inhibition of high dose (80 μg/mL in vitro and 40 mg/kg in vivo)
was reduced rather than enhanced. Furthermore, the computer-
aidedmolecular docking simulations also indicated that TAB had
good binding abilities to the H+/K+-ATPase. Therefore, all of
these results proved that TAB showed the potential drug safety
and druggability because of its widely biological activity and
low-toxicity.
Proton pump inhibitors were widely reported to selectively
inhibit cell proliferation of gastric cancer [23,39,40], induced
gastric cancer apoptosis in a time- and dose-dependentmanner
under acidic environment and had no effect on normal gastric
epithelial cells [41]. For example, pantoprazole could induce
apoptosis of gastric cancer cells selectively, significantly decrease
tumor volume and induce tumor cell apoptosis in large scale
after intratumoral injection in vivo [42,43]. Our present findings
showed that low doses of TABwere able to reduce gastric cancer
cell viability and induce cell apoptosis in acidic environment at
a pH- and dose-dependent manner. On the other side, TAB
nearly has no effect on normal gastric epithelial cells at theseeprazole (10 μg/mL) and TAB (1, 5, 10, 20, 40 and 80 μg/mL) for 24 h. Every
nd H represented untreated cells group, positive group (omeprazole, 10 μg/mL)
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proliferation inhibition to gastric cancer cell line HGC-27, and
has considerable cell apoptosis induction on HGC-27, we
conjectured that its anti-gastric cancer mechanism might be
related to the reduction on gastric acid secretion through
inhibiting the activity of H+/K+-ATPase. TAB could induce
apoptosis in a concentration-dependent manner in HGC-27cell
and had slight effect on normal gastric epithelial cells. This
provides a new approach to the treatment of gastric cancer and
protection of normal gastric epithelial cells.
Literatures report that TAB possesses wide bioactivities
including tumor cell anti-proliferation effects (for example,
human HL-60 leukemia, human KB epidermoid carcinoma,
murine L1210 leukemia cells, Caski, HT-3, and T-24) and
enzyme inhibitory activity (human thrombin, bovine trypsin
and so on) [18,44]. In our previous preliminary experiment
results, TAB also found to possess anti-proliferative effects
against other cancer cell lines including hepatocellular carci-
noma HepG2, lung cancer A549, breast cancer MDA-MB-231,
MCF-7 and gastric cancer cell HGC-27 for 48 h with the IC50
values of 27.14, 43.42, 32.30, 19.44 and 15.91 μg/mL, respec-
tively. In these anti-tumor activities data, TAB seemed to be
more sensitive to gastric cancer cell HGC-27, which signifi-
cantly inhibited HGC-27 cell proliferation in acidic environ-
ment with the IC50 values of 1.54 and 4.19 μg/mL for 24 h at
pH 5.5 and pH 6.5. The anti-tumormechanismof TABmight be
related to theH+/K+-ATPase inhibitory activity by blocking the
ATP-sensitive K+ channel and resulting in the membrane
depolarization, opening the voltage sensitive Ca2+ channel and
increasing the intracellular concentration of Ca2+, selectively
induce apoptosis of gastric cancer HGC-27 cells, but the exact
mechanism required further study.
In this study, our work demonstrates that TAB could inhibit
the H+/K+-ATPase activity both in vitro and in vivo, which was
confirmed by the computer-aided docking simulations. In acidic
environment, lower doses of TAB also exhibited significantly
anti-proliferative effect against gastric cancer HGC-27 cells with
apoptosis-inducing mechanisms in a dose-dependent manner.
The results of this study indicated that the anti-gastric cancer
effects of TAB might be related to the H+/K+-ATPase inhibitory
effects.
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